Answers are grounded in this paper and cite their sources.
A Holy Grail of marrying bioinformatics with structural biology is the design of drugs that precisely affect specific cellular targets. [Ahn and Resing][1] discuss in their Perspective how combining sequence and structural analysis of the catalytic site of protein kinases allowed one group to rationally design molecules that selectively block p90 ribosomal S6 kinase enzymatic activity in cells. [1]: http://www.sciencemag.org/cgi/content/full/308/5726/1266
No takes yet. Share an insight, caveat, or question.
Ahn et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: